Pictet Asset Management Holding SA decreased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 7.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 733,291 shares of the company's stock after selling 55,700 shares during the quarter. Pictet Asset Management Holding SA's holdings in Sanofi were worth $35,367,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in SNY. Charles Schwab Investment Management Inc. lifted its position in shares of Sanofi by 31.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company's stock worth $8,040,000 after purchasing an additional 33,105 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Sanofi by 10.0% during the 3rd quarter. Bank of Montreal Can now owns 256,438 shares of the company's stock worth $14,784,000 after acquiring an additional 23,352 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Sanofi by 408.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 160,339 shares of the company's stock valued at $9,244,000 after acquiring an additional 128,811 shares during the last quarter. Townsquare Capital LLC raised its position in shares of Sanofi by 11.0% during the 3rd quarter. Townsquare Capital LLC now owns 28,248 shares of the company's stock worth $1,628,000 after acquiring an additional 2,808 shares in the last quarter. Finally, Glenmede Trust Co. NA lifted its stake in Sanofi by 0.7% during the third quarter. Glenmede Trust Co. NA now owns 65,996 shares of the company's stock worth $3,803,000 after purchasing an additional 441 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.
Sanofi Stock Performance
Shares of NASDAQ SNY traded down $1.12 during midday trading on Tuesday, reaching $54.34. 3,810,197 shares of the company were exchanged, compared to its average volume of 2,276,146. The stock has a fifty day simple moving average of $55.28 and a 200 day simple moving average of $52.73. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock has a market cap of $137.91 billion, a P/E ratio of 21.82, a PEG ratio of 1.01 and a beta of 0.58. Sanofi has a 1 year low of $45.22 and a 1 year high of $60.12.
Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several brokerages have commented on SNY. The Goldman Sachs Group initiated coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. StockNews.com lowered Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Sanofi presently has a consensus rating of "Moderate Buy" and a consensus price target of $62.50.
Check Out Our Latest Research Report on SNY
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Read More
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
